51571-16-5

Usage

Uses

Used in Pharmaceutical Industry:
2,3-dichloro-6-hydroxybenzaldehyde is used as a reagent for the synthesis of spiropiperidine hydantoins, which are novel antimalarial agents. Its unique structure allows for the development of new drugs that can effectively combat malaria, a disease that affects millions of people worldwide.

Upstream product

• 95-77-2 3,4-dichlorophenol 
• 100-97-0 hexamethylenetetramine 
• 90-02-8 salicylaldehyde 
• 68-12-2 N,N-dimethyl-formamide 
• 204930-39-2 O-3,4-dichlorophenyl N,N-diethylcarbamate 
• 95399-95-4 2,3-Dichloro-6-fluorobenzaldehyde 
• 1435-49-0 3,4-dichlorofluorobenzene 
• 6334-18-5 2,3-dichlorobenzylaldehyde 

Relevant academic research and scientific papers

MLL1 INHIBITORS AND ANTI-CANCER AGENTS

The present invention provides a compound of Formula (I): or an enantiomer, an enantiomeric mixture, or a pharmaceutically acceptable salt thereof; wherein the variables are as defined herein. The present invention further provides pharmaceutical composit

SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS

Compounds of the general formula:processes for the preparation of these compounds, compositions containing these compounds, and the uses of these compounds.

Pd-Catalyzed Ortho C-H Hydroxylation of Benzaldehydes Using a Transient Directing Group

The direct Pd-catalyzed ortho C-H hydroxylation of benzaldehydes was achieved using 4-chloroanthranilic acid as the transient directing group, 1-fluoro-2,4,6-trimethylpyridnium triflate as the bystanding oxidant, and p-toluenesulfonic acid as the putative oxygen nucleophile. The unusual C-H chlorination and polyfluoroalkoxylation reactions signaled the importance of external nucleophiles to the outcome of Pd(IV) reductive eliminations.

WATER-SOLUBLE SHPS AS NOVEL ALKYLATING AGENTS

The present invention relates to compounds according to the structure (I): Where R is —CH3 or —CH2CH2Cl; R′ is C1-C7 alkyl or —CH2CH2Cl; R2 or R4 is OPOsub

Antiangiogenic combination therapy for the treatment of cancer

The present invention provides combinations of a DNA topoisomerase I inhibiting agent and a selective COX-2 inhibiting agent for preventing, treating, and/or reducing the risk of developing a neoplasia disorder in a mammal.

Substituted benzopyran derivatives for the treatment of inflammation

A class of benzopyran, derivatives is described for use in treating cyclooxygenase-2 mediated disorders. Compounds of particular interest are defined by Formula I'wherein X, A1, A2, A3, A4, R, R'', R1 and R2 are as described in the specification.

Substituted benzopyran analogs for the treatment of inflammation

A class of benzopyrans, benzothiopyrans, dihydroquinolines, dihydronaphthalenes, and analogs thereof, is described for use in treating cyclooxygenase-2 mediated disorders. Compounds of particular interest are defined by Formula I'wherein X, A1, A2, A3, A4, R, R'', R1 and R2 are as described in the specification.